Annual revenue rose from KRW 218.4 billion in 2022 to KRW 263.2 billion in 2023 (up 20.5% year on year), KRW 294 billion in 2024 (up 11.7%) and KRW 330.1 billion in 2025 (up 12.3%), marking three consecutive years of growth from 2023 to 2025.
Over the same period operating profit fell from KRW 11.5 billion in 2022 to KRW 792 million in 2023 (down 93.1%), then turned into an operating loss of KRW 13.4 billion in 2024. In 2025 operating profit returned to KRW 15.2 billion, with operating margin at 5.3% in 2022, 0.3% in 2023, -4.6% in 2024 and 4.6% in 2025.
The company attributed the 2025 improvement to a smaller inventory valuation provision, a reduced foreign exchange impact that eased bad-debt costs, higher probiotics sales, and lower personnel costs after the workforce cuts in the second half of 2024.
The 2024 loss was reported to reflect a KRW 11.3 billion inventory provision, a KRW 2.4 billion bad-debt provision tied to the currency spike, higher cost ratios for the flagship probiotic, and delayed domestic launch of the cosmetic.
Profit attributable to controlling shareholders was KRW 12.1 billion in 2022, then a net loss of KRW 10.6 billion in 2023, KRW 20.6 billion in 2024 and KRW 2.81 billion in 2025, so the loss narrowed last year.
Net profit including non-controlling interests was KRW 1.71 billion in 2025, a profit, while the controlling shareholders' share was a loss, so the two figures should be read together.
Operating cash flow was KRW 8.81 billion in 2022, KRW 4.14 billion in 2023, -KRW 13.5 billion in 2024 and KRW 10.3 billion in 2025, turning positive last year.
On a quarterly basis, Q3 2025 revenue of KRW 88.1 billion and operating profit of KRW 2.88 billion gave way to Q4 2025 revenue of KRW 79.9 billion (down 9.3% from the prior quarter) and operating profit of KRW 2.7 billion.
Q1 2026 revenue was KRW 81.8 billion with an operating loss of KRW 526 million, while Q2 2026 revenue rose to KRW 96.2 billion (up 17.5% quarter on quarter) with operating profit of KRW 1.18 billion.
Q3 2026 revenue fell to KRW 83.3 billion, down 13.4% from the prior quarter and 5.5% from a year earlier, and an operating loss of KRW 4.01 billion returned. The controlling shareholders' net loss widened to KRW 7.72 billion in Q3 2026, bringing the last four quarters' total to KRW 13.4 billion.